When to start medicine for gestational diabetes
Official title: Gestational Diabetes and Pharmacotherapy (GAP) – A Randomized Controlled Trial Investigating Timing of Pharmacotherapy Initiation for Patients with Gestational Diabetes
Funded at Medical College of Wisconsin · NIH-11317089 · Data updated 2026-11-12
This project compares starting diabetes medicine earlier versus later in pregnancy to see which approach leads to better health for pregnant people with gestational diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | March 3, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $496,232 |
| NIH project number | 5R01HD108194-05 |
| Project ID | NIH-11317089 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant people diagnosed with gestational diabetes, typically in the second trimester, who are initially managed with diet and exercise and could potentially need medication are the intended participants.
✕Less likely to help
People without gestational diabetes, those with preexisting diabetes who are already on medication, or those who need immediate pharmacotherapy for medical reasons are unlikely to benefit or be eligible.
What this research studies
If you join, you would be followed after a gestational diabetes diagnosis while you try medical nutrition therapy and exercise, and if those measures don’t control your blood sugar you would be randomly assigned to start medicine sooner or later according to the trial plan. Your blood sugar readings, birth outcomes for your baby, and your own health and mood will be tracked through the pregnancy and delivery. The team will compare newborn complications, size at birth, and measures of maternal anxiety and depression between the groups. The goal is to find a clearer, fairer rule for when doctors should add medication so care is more consistent for people of different backgrounds.
Why it matters
Potential benefit: If successful, this could lower newborn complications and create clearer guidelines so future pregnant people get the right diabetes treatment at the right time.
How similar studies have gone: Prior work and smaller studies suggested earlier medication can improve some newborn outcomes, but results are not definitive and concerns like small-for-gestational-age and effects on maternal mental health remain unresolved.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Palatnik, Anna — Medical College of Wisconsin
- Study coordinator: Palatnik, Anna
Related research
Other NIH-funded projects on the same topics.
-
Investigating the best timing for starting medication in pregnant women with gestational diabetes
This study is looking at the best time to start medication for pregnant women with gestational diabetes when diet and exercise aren't enough, to help improve health for both moms and babies while also considering their emotional well-being.
-
Digital twins of the hypothalamus, placenta, and gut to help manage gestational diabetes
A study using computer-based models of a pregnant person’s brain, placenta, and gut to better understand how gestational diabetes develops and how to tailor treatments.
-
IGF factors and binding proteins in gestational diabetes and fetal growth
A study in pregnant people looks at how insulin-like growth factors and their binding proteins affect gestational diabetes and how a baby grows.
-
STRONG group prenatal care to reduce gestational diabetes in American Samoa
A Yale-led program tests a group prenatal care approach to lower gestational diabetes among pregnant Pacific Islander women in American Samoa.
-
Pancreatic beta cells, oxidative stress, and gestational diabetes
A study is exploring how oxidative stress and changes in pancreatic beta cells during pregnancy may contribute to gestational diabetes and future diabetes risk for both mother and baby.
-
NDPP-MAP: A tailored online-hybrid program to reduce long-term health risks after pregnancy with gestational diabetes
A patient-friendly program adapts a proven diabetes prevention approach to help women who had gestational diabetes lower their risk of type 2 diabetes and heart problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.